Free Trial

Y-mAbs Therapeutics Q4 2024 Earnings Report

Y-mAbs Therapeutics logo
$4.50 +0.07 (+1.58%)
As of 04/1/2025 04:00 PM Eastern

Y-mAbs Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.02

Y-mAbs Therapeutics Revenue Results

Actual Revenue
$26.50 million
Expected Revenue
$26.70 million
Beat/Miss
Missed by -$206.00 thousand
YoY Revenue Growth
N/A

Y-mAbs Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Y-mAbs Therapeutics Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Y-mAbs Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Y-mAbs Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your email.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

View Y-mAbs Therapeutics Profile

More Earnings Resources from MarketBeat